Xeris Biopharma Holdings Inc

NASDAQ:XERSUnited States

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Contact Information

Headquarters

1375 West Fulton Street, Suite 1300CHICAGO, IL, United States 60607

Phone

302-658-7581

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Paul Edick

President, Chief Operating Officer

John Shannon

Chief Financial Officer

Steven Pieper

Senior Vice President - Global Development and Medical Affairs

Kenneth Johnson

Chief Legal Officer, Corporate Secretary

Beth Hecht